Error loading player: No playable sources found
5390
AGA FDA Town Hall
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
This session was jointly developed by AGA and representatives from the Division of Gastroenterology at the FDA Center for Drug Evaluation and Research. This session will give health care professionals and clinical trialists a chance to hear directly from FDA representatives about the agency's thinking behind the most recent product approvals and guidance documents impacting the GI community. The 2023 session will address new therapies for IBD, EoE, and C. difficile infection, as well as the agency's current thinking on artificial intelligence-enabled medical devices.
This session was jointly developed by AGA and representatives from the Division of Gastroenterology at the FDA Center for Drug Evaluation and Research. This session will give health care professionals and clinical trialists a chance to hear directly from FDA representatives about the agency's thinking behind the most recent product approvals and guidance documents impacting the GI community. The 2023 session will address new therapies for IBD, EoE, and C. difficile infection, as well as the agency's current thinking on artificial intelligence-enabled medical devices.
Moderators
University of Tennessee Health Science Center
Middleburg Consultants
Related Products
AGA Beyond Gut Bacteria: Transkingdom Interactions Underlying GI Diseases
Through the history of gut microbiome research, basic, translational, and clinical studies revealed many critical roles played by gut-resident bacteria in affecting human health and disease…
AGA Aryl Hydrocarbon Receptor in Gastrointestinal Disease
The role of nutrition and the microbiome is evident in IBD and functional bowel disorders. The microbiome can affect the way nutrients are metabolized in bioactive components. It is of important to understand the molecular sensors of such metabolized components…
AGA Microbiome Therapeutics on the Horizon
This session highlights thecurrent FDA approved microbiome therapeutics and their applications and the exciting avenues being pursued for the next generation of microbiome therapeutics using gene editing and synthetic microbial communities…
AGA The Mucosal Immune Response and Nonimmune Cells in IBD
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
